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Angiogenic inhibitors function by blocking tumor cell signals used to recruit host 
tissue vasculature to the tumor site, thereby depriving the cancer of the nutriment needed 
for further expansion. The development and implementation of angiogenic inhibitors in 
conjunction with standard chemotherapy agents has increased progression-free survival 
but not overall patient survival. It is hypothesized that chronic exposure to large doses of 
AAT drugs worsens hypoxic conditions within the tumor mass, selectively stimulating 
aggressive cancer stem cell populations to grow and proliferate.  
In this study, the expression of the CSC biomarkers ALDH1, DLL1, and EpCAM 
were evaluated in breast cancer tumors grown in mouse models for varying doses of 
angiogenic inhibitor DC101 using a threshold analysis technique developed in-house. 
SUM149 triple-negative breast cancer cells were grown in athymic nude mice and 
administered either 10mg/kg, 40mg/kg, or 120mg/kg DC101, corresponding to “Low 
Dose”, “Medium Dose”, and “High Dose”, respectively. Following a period of several 
days, the tumors were harvested, sectioned into slices at specific depths, and stained for 
one of each biomarker. Stained sections were scanned into a computer, where images 
were subjected to a series of coded protocols written in-house for Matlab or IDL. Images 
were segmented to remove non-target background pixels and co-registered to a series of 





applied to separate biomarker-positive image pixels from those pixels deficient in the 
biomarker stain. Pixel values were counted for both the control tumor slides and those 
having received DC101 exposure. Values were compared to evaluate changes in 
biomarker expression with variations in dose concentration. Pixel values were also 
compared between corresponding slices stained for different biomarkers in order to 
determine the prevalence of spatially-overlapping regions. 
Experimental results demonstrate a significant (p < 0.05) decrease in ALDH1 and 
DLL1 biomarker expression for the MD groups compared to controls, and elevated 
expression in the HD group compared to the LD and MD groups for the same biomarkers. 
Changes were most dramatic in the expression of the DLL1 biomarker. EpCAM 
expression did not vary significantly (p < 0.05) with dose. Variations in overlap between 
ALDH1 and EpCAM suggest that expression of the two biomarkers may be linked, while 
DLL1 overlap data suggests that DLL1 expression is independent of ALDH1 and 
EpCAM. Through a combination of perfusion imaging and biomarker expression, our 
data suggest that “medium dose” concentrations of 40mg/kg of DC101 can affect 
normalization of tumor vasculature within our mouse models, thereby alleviating hypoxia 
within the tumor microenvironment. While our ALDH1 quantification results provide 
some validation for our technique, future goals should focus on further validation through 
additional quantification of known biomarkers, the incorporation of PCA, and the use of 







CHAPTER 1. INTRODUCTION 
1.1 Antiangiogenic Therapy 
Research into the treatment of cancers has yielded a multitude of different 
approaches and techniques. While a growing body of attention has focused on genomics 
for a more personalized experience, existing treatments most commonly include radiation 
exposure in conjunction with a carefully-planned regimen of cytotoxic chemical agents. 
Among those drugs considered for cancer treatment are a class referred to as angiogenic 
inhibitors, which attempt to stem tumor growth through the inhibition of blood vessel 
formation. Despite setbacks from clinical trials, the potential of angiogenic inhibitors 
remains a subject of ongoing study.  
Angiogenesis is characterized in normal tissue by the formation of capillary micro 
vessels in response to migrating and proliferating endothelial cells. Regulated by a host of 
inhibitors and growth factors1, angiogenesis is a critical component in wound repair, 
tissue development, and reproduction. While this process typically transpires over a self-
limited period of weeks or months, pathology-linked angiogenesis can persist chronically 
for years. Such angiogenesis-dependent diseases include age-related macular 
degeneration, rheumatoid arthritis, atherosclerosis, and cancer; angiogenesis is critical to 
fueling the prolonged growth of neoplasms and their associated metastases. 
Originally conceptualized in the late 1970s1,2, antiangiogenic therapy was first 





existing chemotherapy agents that target specific components of mitotic division, the 
theory behind AAT centers on the notion of cellular starvation: Tumors must sustain their 
constant expansion through the recruitment of new blood vessels, diverting oxygen and 
nutriment into their growing mass. By blocking blood vessel recruitment, it was theorized 
that sustained cell division would no longer be possible as supplies of glucose and 
oxygen were gradually exhausted. This alternative approach offered the potential for 
greater sparing of healthy tissue: While cell division-targeting drugs would exhibit 
cytotoxic effects on all dividing cells in the body, including normal cells, AAT drugs 
would only block the formation of new blood vessels, leaving existing vasculature intact. 
 Research into this technique has led to the development of a variety of functional 
AAT drugs, the earliest of which began clinical trials in the mid-1990s1. Bevacizumab, a 
monoclonal antibody approved in 2004 for the treatment of colorectal cancer by the US 
Food and Drug Administration, was the first of these new drugs developed solely as an 
angiogenic inhibitor and is one of the better-studied of the emerging AAT agents. 
Marketed under the trade name Avastin, the drug disrupts the activity of vascular 
endothelial growth factor A (VEGF-A), one of the leading promoters of angiogenesis1,3,4. 
Similar drugs such as the kinase inhibitor sunitinib and monoclonal antibody DC101 
were developed to target VEGFR kinase activity5 and antigen binding5,6, respectively. 
 After years of studies accumulated, a common trend in AAT treatment of 
cancerous lesions manifested: While angiogenic inhibitors may provide positive clinical 
benefits against established tumor cell populations, they are not increasing overall patient 
survival. Bevacizumab was shown to confer no significant benefit to overall patient 





to increase the rate of spontaneous metastasis in laboratory mice5-7 as well as increase 
long-term tumor invasiveness6,7. These results suggest a relationship exists between AAT 
drugs and metastatic growth.  
One hypothesis purports that hypoxic conditions, which have already been 
implicated in decreased treatment effectiveness due to the decreased availability of 
reactive oxygen species8, are being worsened by exposure to angiogenic inhibitors. The 
tortuous and abnormal development of vasculature within cancerous lesions creates 
natural regions of chronic hypoxia, which are further intensified by rapid degeneration of 
tumor vasculature within the tumor mass. Such developments could inadvertently select 
for those cells which can survive under nutrient-starved conditions and therefore promote 
the growth of more aggressive cancer cells9,10. Additionally, extrapolating from gene 
regulation mechanisms identified in human embryogenesis, it is theorized that hypoxia 
may play a role in the activation of certain growth-specific gene expression pathways in 
cancer cells9. 
  To address these circumstances, some researchers have pursued alternative AAT 
techniques: Instead of ablating blood vessel recruitment with high doses of angiogenic 
inhibitors, lower doses can be used to normalize tumor vasculature. Vasculature 
normalization can have the dual effect of increasing oxygen perfusion to the tumor mass, 
thereby alleviating hypoxic conditions and the various associated complications, and 
better allowing chemotherapy agents to access cancer cells within the tumor interior9,10. 
Identifying dose concentrations that achieve the desired normalization effect is the 





1.2.1 Cancer Stem Cell Hypothesis 
Stem cells are undifferentiated cells within a tissue that are functionally capable of 
indefinite division and self-renewal, thereby providing a regenerative pool for continuous 
tissue replenishment. Homeostatic regulations for cells within a tissue are maintained at 
the stem cell level11. Following division, one of the two resulting cells will retain its 
undifferentiated, stem-like properties, while the other cell will have begun to differentiate 
into a progenitor cell. Unlike its predecessor, a progenitor cell loses the capacity to 
sustain indefinite division and will begin to express the properties and characteristics of 
the more mature, fully differentiated cells of the surrounding tissue type. 
With regards to the multi-step model of carcinogenesis, wherein normal cells may 
become cancerous after sustaining several uncorrected mutations over multiple 
generations, it is unsurprising that loss of homeostatic regulation can cause normal adult 
stem cells to divide uncontrollably. These cancer stem cells, stem-like cells whose 
homeostatic mechanisms have been altered or subverted, can arise from either mutated 
adult stem cells or progenitor cells that have dedifferentiated back into stem cells10-13. 
The CSC hypothesis maintains that these stem-like cancer cells are the basis of self-
propagating tumors: Small subpopulations of CSCs maintain growth of the larger tumor, 
with daughter cells differentiating into mature cells of the CSC tissue type with finite 
growth capacities11. 
Experimental evidence strongly supports the existence of CSCs10-13. Additional 
evidence suggests that hypoxic tissue conditions induce expression of certain 
transcription factors which contribute to tumor progression9 and may cause differentiated 





CSC populations makes its alleviation a high priority for the improvement of cancer 
therapy outcomes. 
1.2.2 CSC Biomarkers 
Studies of tumor histology have provided a means of visualizing CSC populations. 
The effect of a drug, for example, on CSC populations can be monitored through 
quantifying the cells within a tumor volume that express specific CSC biomarkers. 
Multiple CSC biomarkers have been identified in previous experiments, including 
combinations of clusters of differentiation proteins11,14, cell surface adhesion molecules15, 
and cytosolic enzymes12,16. 
One such biomarker is ALDH1, a detoxifying enzyme that catalyzes the oxidation 
of aldehyde groups into carboxylic acids. Its ability to metabolize retinol into retinoic 
acid is under investigation for its role in stem cell differentiation12,16. Found 
predominantly in liver cells due to its metabolic significance, overexpression has been 
associated with negative clinical prognosis for malignant human mammary stem cells12,16. 
ALDH1 expression on the exterior of the plasma membrane has been demonstrated in 
both CSCs and progenitor cells, while internal ALDH expression is strictly associated 
with the undifferentiated stem cells16. Antibody staining techniques may be utilized to 
identify ALDH expression on cell surfaces, while the ALDEFLUOR assay has been used 
to identify cells with cytosolic ALDH expression.  
EpCAM is a transmembrane glycoprotein found frequently on the basolateral 
surfaces of various epithelial cells, enabling cell-cell adhesion through calcium-
independent pathways15,17. Increased EpCAM activity correlates inversely with standard 





and differentiation and increasing epithelial cell proliferation17. EpCAM is being 
investigated as a potential target for cancer therapy due to its documented overexpression 
in a variety of carcinomas, including those originating in the pancreas, breast, prostate, 
and colon15,17. 
DLL1 is a delta ligand homolog in humans that participates in multiple Notch 
signaling pathways: Ligands are passed from a signaling cell to the Notch cell surface 
domain, which initiates a series of cleavage events that in turn release transcription 
factors into the intracellular space. It is perhaps best known for its role in directing 
progenitor cell differentiation, promoting characteristics of T-cell precursors while 
blocking progression into B-cells19. Additionally, Notch signaling via DLL1 regulates 
stem cell renewal and differentiation in the lumen of normal breast tissue, a property that 














CHAPTER 2. METHODOLOGY 
2.1 Specific Aims 
One goal of this study is to identify a dose window in which biomarker-expressing 
cancer cell populations are reduced, which will provide insight into the optimum dose 
concentration for tumor vasculature normalization. Another goal is to simultaneously 
evaluate the validity of our simple threshold technique and the biomarkers it uses for 
CSC population monitoring. To that end, expression of ALDH1, EpCAM, and DLL1 will 
be assessed in breast cancer tumors. The three specific aims of the study are as follows: 
1) Demonstrate relative variations in biomarker expression between biomarkers in 
breast tumor tissue 
2) Demonstrate changes in biomarker expression with variations in administered 
angiogenic inhibitor  
3) Observe changes in overlapping regions of biomarker expression 
 
Firstly, it is imperative to quantify a baseline of existing biomarker expression in 
tumor tissue, as changes to this baseline will demonstrate the effects of the angiogenic 
inhibitor on CSC populations. To achieve this objective, breast cancer tumors grown in 
live mouse models will be sampled, stained via immunohistochemistry techniques, and 
biomarker expression will be quantified through image processing via Matlab and IDL 





Once a baseline has been established, assessments can be made regarding the 
effect that different concentrations (low dose, medium dose, and high dose) of angiogenic 
inhibitor have on the target biomarkers. After completing a specific drug administration 
protocol, breast cancer tumors grown in athymic nude mice will be sampled, stained via 
IHC, and biomarker expression will be quantified for each drug concentration through 
image processing via Matlab and IDL codes developed in-house. Values obtained from 
this analysis will be compared to those obtained for aim 1 to determine the effect of the 
inhibitor on biomarker expression. 
Finally, overlapping regions that register as positive for different biomarker stains 
sections will be quantified in order to assess the significance of biomarker spatial 
distributions. Using slides processed during the first two aims, different stained sections 
corresponding to similar cut depths will be analyzed simultaneously using IDL code 
developed in-house.  
Validation of the proposed threshold-based technique will be accomplished by 
comparing ALDH1 expression results with existing quantification data acquired in a 
separate experiment12, which used a fluorescence-activated cell sorting technique for the 
same tissue type. The feasibility of using EpCAM and DLL1 as biomarkers for CSC 
populations will be determined based on their expression patterns with respect to changes 









2.2  Cell Growth and Image Acquisition 
Thirteen athymic nude mice, separated into roughly equal groups (group 1 
contained four mice, while groups 2, 3, and 4 contained three mice each), were imaged 
with photoacoustic computed tomography (PCT-S) and dynamic contrast computed 
tomography (DCE-CT) to determine SaO2 levels and fractional vascular volume, 
respectively. All mice were given intraperitoneal injections of SUM149 triple-negative 
inflammatory breast cancer cells and allowed time for tumors to grow to an average 
8.5mm- to 9.0mm-diameter size. Mice groups 2, 3, and 4 were then administered 
10mg/kg (corresponding to “low dose”), 40mg/kg (corresponding to “medium dose”), 
and 120 mg/kg (corresponding to “high dose”) respectively, of the DC101 monoclonal 
antibody specific to VEGFR2. DC101 was administered three times daily, at three-day 
intervals, over a seven-day period via intraperitoneal injection.  
One day following final dose administration, mice were again imaged using PCT-S 
and DCE-CT techniques to assess perfusion and fractional vascular volume, respectively. 
All mice were then sacked and tumors were excised by the pathology department at 
Indiana University Medical Center (Indianapolis, IN). Tumors were sectioned in half and 
soaked in 10% formalin buffer solution for 24-48 hours, after which they were transferred 
to 70% ethyl alcohol solution until they could be paraffin fixed. Initial cuts were taken at 
1.0mm increments from the original section (read: center of original tumor mass), with 
additional slices taken at 4-6μm from each cut site. Slices corresponding to a specific cut 
depth (1.0mm, 2.0mm, or 3.0mm) were mounted on glass slides and stained: Each 
individual slice received either Hematoxylin with Eosin counterstain, or biomarker-






Histology slides were imaged via Olympus BX41 Light Microscope using Cellcens 
Dimensions software and DP72 camera (Olympus, PA). Images were taken using a 





2.3 Image Segmentation 
Segmentation script was devised in-house (Mario Dzemidzic, IUPUI) in MatLab 
and applied to each image. The segmentation code separates tissue from the image 
background in accordance with the process described in Brett Shoelson’s Webinar 
(Medical Imaging Workflows with Matlab; http://www.mathworks.com/videos/medical-
imaging-workflows-with-matlab-81850.html).  JPEG color images are converted to 
grayscale and binarized using the automated Otsu’s method. The resulting image masks 
are then cleared of non-tissue objects near the image borders. When appropriate, manual 
thresholds can be applied on a slice-by-slice basis using custom Matlab scripts. The 
resulting output images include the grayscale mask, individual color masks, and the 





Figure 2.1: Tumor sections were treated separately with antibodies for ALDH1 (A), 
EpCAM (B), and DLL1 (C) before being stained with DAB stain and Hematoxylin 
















2.4 Image Co-registration 
Co-registration script was devised in-house (Mario Dzemidzic, IUPUI) in MatLab 
and applied to those color images that had undergone segmentation. Tissue sections 
stained with H&E are selected as “fixed”, or stationary, images to which other “moving” 
stained sections can be co-registered. Moving images are initially resampled using spline 
interpolation and are either zero-padded or edge-trimmed to match the size and pixel 
dimensions of their corresponding fixed image. The algorithm determined any necessary 
geometric transformations using the imgregtform function in the Image Processing 
Toolkit. Optimization was achieved by accounting for sectioning-related tissue 
distortions and minor spatial offsets during the staining process. Co-registration was 
performed in three distinct iterations: The first two iterations used similarity translations 
A B 
Figure 2.2: Segmentation script in Matlab uses the automated 
Otsu’s method to remove background pixels and all non-target 
tissue impinging from outside the image boundaries. (A) denotes 






(rotational, translational, and scaling) to match the moving image to the fixed image as 
best possible, while the third iteration accounted for both similarity and shearing which 
may have occurred during tissue handling. Output JPEG images were saved for each 
iteration of shifts to the moving image, with those resulting from the final iteration being 
used for subsequent steps.   
 
2.5 Image Thresholds 
Code to apply thresholds was developed in-house in IDL and applied to all co-
registered images. Thresholds were determined individually for each biomarker stain 
through qualitative, visual assessment of the segmented images based on the quantity of 
counterstain present in a given pixel; thresholds were designed to exclude pixels with 
high blue-channels values, corresponding to high and low concentrations of counterstain 
and primary stain, respectively. Sets of tissue sections stained for the same biomarker 
then had thresholds applied to them such that pixels containing sufficient counterstain to 
constitute “negative” biomarker expression were assigned one value, “positive” pixels 
A B C 
Figure 2.3: Segmented images (A) are translated, rotated, and resized (B) to co-register to 






were assigned a different value, and those pixels rendered as “background” by the 
segmentation code were assigned a zero value. To compensate for potential errors in the 
co-registration process, images were binned at 2x (2x2 pixel squares per bin). Both 







2.6 Image Quantification 
Quantification code was developed in-house using IDL and was applied to JPEG 
images after thresholds. For each run of the script, two images of corresponding section 
depth and different biomarker stain were read into the program and the number of 
“positive” and “negative” pixel values were counted for each image. The two images 
were then compared against each other, and overlapping values (positive/positive, 
positive/negative, negative/positive, and negative/negative) were counted. The results 
were displayed along with the image dimensions in the IDL interface.  
Biomarker presence was noted as a percentage of the total tissue slice volume. Slice 
values for a given tumor were averaged to estimate the average percentage of the total 
tumor volume. The resulting values for each tumor were averaged together to acquire an 
A B 
Figure 2.4: Co-registered images (A) are exposed to a manually-set threshold value, 
specific to each biomarker, which separates pixels into “positive” and “negative” 







aggregated average of the percentage of biomarker per total tumor volume. For specific 
aim 1, the average percentages of total tumor volume for each control cohort were 
compared. For specific aim 2, control results were compared to averages resulting as a 
function of DC101 dose for each biomarker. For specific aim 3, average values for 
regions of overlap between biomarkers were compared as a function of DC101 dose. All 
statistical significance was determined using p-values derived from two-tailed T tests 






CHAPTER 3.  RESULTS 
3.1 Specific Aim 1 
Threshold values used to separate pixels for positive and negative biomarker 
expression for ALDH1, EpCAM, and DLL1 were found to be 155, 50, and 70, 
respectively. Results for average biomarker percentage by total tissue volume are 
displayed in Table 3.1 and Figure 3.1. Average biomarker expression per control tumor 
was found to be 3.61%±1.39, 3.54%±3.80, and 18.39%±13.70 for ALDH1, EpCAM, and 





Figure 3.1: Biomarker quantification for control tumors, 








































3.2 Specific Aim 2 
Results for ALDH1 dose response to DC101 are displayed in Figure 3.2. Average 
ALDH1 expression for LD (10mg/kg), MD (40mg/kg), and HD (120mg/kg) was found to 
be 1.81%±0.84, 1.05%±0.10, and 1.90%±0.48, respectively. Statistically significant (p < 
0.05) differences were most closely observed between ALDH1 expression in the control 
tumors and the MD tumors, with non-trivial (p < 0.10) changes observed between control 
and LD tumors, control and HD tumors, and MD and HD tumors.  
Results for EpCAM dose response to DC101 are displayed in Figure 3.3. Average 
EpCAM expression for LD, MD, and HD tumors was found to be 2.19%±0.85, 
1.08%±0.58, and 1.83%±0.22, respectively. No statistically significant differences were 
observed between any of the different tumor groups. 
 
 
Table 3.1: Average biomarker expression per tumor, 
expressed as a percentage of total tumor volume 
  ALDH1 (%) EpCAM (%) DLL1 (%) 
M1 4.8071 9.2065 12.6372 
M2 2.1570 1.3642 1.7834 
M3 2.6970 1.3688 31.0833 
M4 4.7979 2.2319 28.0369 
Average 3.6148 3.5428 18.3852 




















Figure 3.2: ALDH1 dose response to DC101, expressed in terms of average % of total 















Results for DLL1 dose response to DC101 are displayed in Figure 3.4. Average 
DLL1 expression for LD, MD, and HD tumors was found to be 2.44%±0.61, 
2.74%±0.1.54, and 14.10%±3.58, respectively. Statistically significant (p < 0.05) 
differences were observed between the LD and HD tumors and MD and HD tumors. 
Figure 3.3: EpCAM dose response to DC101, expressed in terms of 
average % of total tumor tissue volume 
 
 















































































3.3 Specific Aim 3 
Results for the overlapping ALDH1/EpCAM expression response to DC101 dose 
from both non-binned and binned images are displayed in Figure 3.5 and Tables 3.2 and 
3.3. Average overlap for controls, LD, MD, and HD tumor groups was observed to be 
0.112%±0.070, 0.049%±0.019, 0.042%±0.005, and 0.092%±0.008, respectively, for non-
binned images. For binned images, average overlap for controls, LD, MD, and HD tumor 
groups was observed to be 0.065%±0.073, 0.022%±0.012, 0.012%±0.001, and 
0.030%±0.004, respectively. Statistically significant (p < 0.05) differences were observed 
between LD and HD tumor groups both non-binned images and MD and HD tumor 
groups for both binned and non-binned images. Statistically significant (p < 0.05) 
differences were also observed between binned and non-binned images for both the MD 
and HD tumor groups. 
  
Figure 3.4: DLL1 dose response to DC101, expressed in terms of the 




















































Average Dose Comparison - Non-Binned vs Binned 
  Control (%) 10mg/kg (%) 40mg/kg (%) 120mg/kg (%) 
No Bins 0.1119 0.0494 0.0417 0.0917 
Binned 0.0648 0.0221 0.0124 0.0304 
p 0.3874 0.1157 0.0072 0.0011 
Dose Response Comparison - Non-Binned and Binned 
  Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD 
No Bins 0.1720 0.1720 0.6066 0.5621 0.0454 0.0014 
Binned 0.3280 0.3280 0.4146 0.2884 0.3517 0.0125 
Figure 3.5: ALDH1/EpCAM dose response to DC101 for non-binned and 
binned images 
 
Table 3.3: Associated p-values of ALDH1/EpCAM dose 
response relationships for non-binned and binned images 
results 
 
Table 3.2: Average ALDH1/EpCAM expression for non-binned 
and binned image results, expressed as a percentage of the total 
tumor volume. P-values are included for comparison between 

































Dose Response of ALDH1/EpCAM Overlap to 








ALDH1/EpCAM overlap expressed in terms of total ALDH1-positive and 
EpCAM-positive expression regions are displayed in Figure 3.6 and 3.7. Of the total 
ALDH1-positive populations identified, regions of overlap with EpCAM-positive 
populations accounted for 3.313%±1.378, 3.503%±2.408, 4.260%±0.753, and 
5.121%±0.590 for controls, LD, MD, and HD tumor groups, respectively, in non-binned 
images; for binned images, overlap accounted for 2.100%±1.626, 1.961%±1.028, 
1.981%±0.436, and 2.649%±0.426 for controls, LD, MD, and HD tumor groups, 
respectively. For EpCAM-positive regions, overlap with ALDH1 accounted for 
5.714%±2.111, 3.618%±1.978, 4.828%±2.225, and 6.890%±2.381 for controls, LD, MD, 
and HD tumor groups, respectively, in non-binned images; in binned images, overlap 
accounted for 3.658%±1.743, 2.245%±0.994, 2.660%±1.538, and 4.164%±1.832 for 
controls, LD, MD, and HD tumor groups, respectively. No statistical significance (p < 









Figure 3.6: ALDH1/EpCAM dose response to DC101, expressed in 































Results for the overlapping ALDH1/DLL1 expression response to DC101 dose 
from both non-binned and binned images are displayed in Figure 3.8 and Tables 3.4 and 
3.5. Average overlap for controls, LD, MD, and HD tumor groups was determined as 
being 0.775%±0.726, 0.069%±0.005, 0.050%±0.019, and 0.220%±0.057, respectively, in 
the non-binned image sets. For the binned images, average overlap was found to be 
0.642%±0.658, 0.032%±0.013, 0.019%±0.009, and 0.115%±0.034 for the control, LD, 
MD and HD tumor groups, respectively. Statistically significant (p < 0.05) differences 
were observed between LD and HD tumor groups and MD and HD tumor groups for both 
non-binned and binned images. Additionally, statistically significant (p < 0.05) 
differences were observed between non-binned and binned image sets for the LD tumor 
groups, with non-trivial (p < 0.10) differences observed between non-binned and binned 
images for the MD and HD tumor groups. 
Figure 3.7: ALDH1/EpCAM dose response to DC101, expressed in 




















% EpCAM in ALDH1/EpCAM Overlap to DC101, 


























ALDH1/DLL1 overlap expressed in terms of total ALDH1-positive and DLL1-
positive expression regions are displayed in Figure 3.9 and 3.10. Of the total ALDH1-
positive populations identified, regions of overlap with DLL1-positive populations 
accounted for 19.101%±15.313, 4.658%±2.013, 4.891%±1.975, and 12.598%±0.577 in  
Average Dose Comparison - Non-Binned vs Binned 
  Control (%) 10mg/kg (%) 40mg/kg (%) 120mg/kg (%) 
No Bins 0.7754 0.0686 0.0502 0.2199 
Binned 0.6417 0.0324 0.0189 0.1146 
P 0.7940 0.0234 0.0839 0.0653 
Dose Response Comparison - Non-Binned and Binned 
  Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD 
No Bins 0.1465 0.1465 0.2232 0.2255 0.0435 0.0266 
Binned 0.1611 0.1611 0.2074 0.2078 0.0383 0.0319 
Table 3.5: Associated p-values of ALDH1/DLL1 dose response 
relationships for non-binned and binned images results 
 
Figure 3.8: ALDH1/DLL1 dose response to DC101 for non-binned and 
binned images 
Table 3.4: Average ALDH1/DLL1 expression for non-
binned and binned image results, expressed as a percentage 
of the total tumor volume. P-values are included for 






























Dose Response of ALDH1/DLL1 Overlap to 


















controls, LD, MD, and HD tumor groups in the non-binned image sets. In the binned 
images, overlap accounted for 18.704%±16.943, 2.800%±0.992, 2.767%±1.309, and 
9.520%±0.570 in controls, LD, MD, and HD tumor groups. Statistically significant (p < 
0.05) differences were observed between LD and HD tumor groups and MD and HD 
tumor groups for both non-binned and binned image sets.  
Of the total DLL1-positive populations identified, regions of overlap with ALDH1-
positive populations account for 5.112%±2.447, 3.249%±0.698, 2.934%±1.602, and 
1.774%±0.252 of controls, LD, MD, and HD tumor groups, respectively, in non-binned 
image sets. For the binned images, overlap accounts for 4.115%±1.863, 1.951%±0.074, 
1.684%±0.996, and 1.018%±0.216 of controls, LD, MD, and HD tumor groups, 
respectively. Non-trivial (p < 0.10) differences were observed between control and HD 
tumor groups and LD and HD tumor groups in the non-binned image sets; in the binned 
image sets, these same differences became more significant (p < 0.05).  
Figure 3.9: ALDH1/DLL1 dose response to DC101, expressed in terms 



































Overlapping EpCAM/DLL1 expression response to DC101 dose from both non- 
binned and binned images are displayed in Figure 3.11 and Tables 3.6 and 3.7 Average 
overlap for controls, LD, MD, and HD tumor groups was observed to be 0.68%±0.660, 
0.067%±0.038, 0.070%±0.049, and 0.591%±0.076, respectively, for the non-binned 
image sets. For the binned image sets, average overlap was found to be 0.550%±0.567, 
0.033%±0.023, 0.040%±0.035, and 0.499%±0.074, respectively. Statistically significant 
(p < 0.05) difference were observed between the LD and HD groups and MD and HD 
groups for both binned and non-binned images. No statistically significant differences 
were observed between non-binned and binned tumor groups. 
EpCAM/DLL1 overlap expressed in terms of total EpCAM-positive and DLL1-
positive expression regions are displayed in Figure 3.12 and 3.13. Of the total EpCAM-
positive populations identified, regions of overlap with DLL1-positive populations 



















Figure 3.10: ALDH1/DLL1 dose response to DC101, expressed in 


























controls, LD, MD, and HD tumor groups, respectively, in the non-binned image sets. For 
the binned image sets, overlap accounted for 19.457%±13.680, 2.083%±0.871, 
4.123%±2.612, and 27.966%±2.303. Statistically significant (p < 0.05) differences were 
Average Dose Comparison - Non-Binned vs Binned 
  Control (%) 10mg/kg (%) 40mg/kg (%) 120mg/kg (%) 
No Bins 0.6801 0.0674 0.0703 0.5911 
Binned 0.5499 0.0325 0.0397 0.4991 
p 0.7750 0.2548 0.4337 0.2079 
Dose Response Comparison - Non-Binned and Binned 
  Ctrl-LD Ctrl-MD Ctrl-HD LD-MD LD-HD MD-HD 
No Bins 0.1601 0.1601 0.8061 0.9405 0.0020 0.0012 
































Table 3.6: Average EpCAM/DLL1 expression for non-binned 
and binned image results, expressed as a percentage of the 
total tumor volume. P-values are included for comparison 
between non-binned and binned image results 
 
Table 3.7: Associated p-values of EpCAM/DLL1 dose response 
relationships for non-binned and binned image results 
 
Figure 3.11: EpCAM/DLL1 dose response to DC101 for non-






observed between LD and HD tumor groups and MD and HD tumor groups for both non-
binned and binned image sets. Non-trivial (p < 0.10) differences were also observed 
between controls and LD tumor groups and controls and MD tumor groups for both non-
binned and binned image sets. No significant (p < 0.05) differences were observed 










 Of the total DLL1-positive populations identified, overlap with EpCAM-
positive populations accounted for 5.321%±6.280, 2.793%±1.067, 2.421%±0.797, and 
4.279%±1.368 in controls, LD, MD, and HD tumor groups, respectively, from non-
binned image sets. For the binned image sets, overlap accounted for 4.605%±6.251, 
1.636%±0.815, 1.435%±0.775, and 4.096%±1.165  in controls, LD, MD, and HD tumor 
groups, respectively. Statistically significant (p < 0.05) differences were observed 
between LD and HD tumor groups and MD and HD tumor groups for the binned image 
sets. No statistically significant (p < 0.05) differences were observed between binned and 




















Figure 3.12: EpCAM/DLL1 dose response to DC101, expressed in 

































Figure 3.13: EpCAM/DLL1 dose response to DC101, expressed in 









CHAPTER 4. CONCLUSION, DISCUSSIONS, AND FUTURE AIMS 
4.1 Technique Validation 
Utilizing our in-house Matlab and IDL scripts, our threshold-based quantification 
technique estimated that ALDH1-positive pixels accounted for an average of 3.61%±1.39 
of the SUM149 control tumor volumes. These findings correlate strongly with those 
determined by Charafe-Jauffret et al12, who used the fluorescence-based ALDEFLOUR 
assay to arrive at a similar conclusion (values range between 3.54% ± 1.73 and 5.49% ± 
3.36 for the same cell type). Our agreement with independently-determined data obtained 
through alternative means lends credence to the validity of our approach. The nearly five-
fold abundance of DLL1 expression in control tumors compared to ALDH1 expression 
suggests that the threshold value chosen for DLL1 may need to be modified, however this 
cannot yet be verified due to lack of existing quantification data for both EpCAM and 
DLL1 in the SUM149 breast cancer cell line in the literature. For this reason, future uses 
of this technique should involve previously-quantified biomarkers for further validation 
purposes.  
Significant variations were observed in the control populations for both EpCAM 
and DLL1, with ALDH1 variations proving to be consistent with those values previously-
reported. This may be less due to the technique and more so to the underpowered nature 
of our study; only four mouse tumors were used to characterize the control populations, 
which may have been insufficient to adequately cover the full range of expression values. 







points that greatly alter the total average: Mouse tumor 1 in the EpCAM group is nearly a 







the DLL1 group is two orders of magnitude smaller than the other tumors in its group. 
Upon closer inspection, the Mouse 2 control tumor for DLL1 appeared to express almost 
no DLL1 (Figure 4.1.1), either due to an error in the staining process or to abnormally 
low expression of DLL1. The Mouse 1 control tumor did not appear to have anything 
wrong with its staining after closer inspection (Figure 4.1), suggesting that the sample 
size may have been too small to adequately cover the range of values for EpCAM 
expression. Removing these points improved the deviations, changing the average 
EpCAM and DLL1 expressions to 1.655 %±0.500 and 23.919%±9.888, respectively, 
however the new averages were not found to vary from the original values by a 
statistically significant difference. 
The co-registration component adds an additional source of uncertainty, as minute 
depth-based differences between tissue slices can hinder precise alignment of associated 
images, which in turn can lead to false-positive and false-negative results during the 
counting phase. Individual biomarker quantification (Aim 2) should not have been 
affected by this step, as no inter-comparison between co-registered images was needed to 
  ALDH1 (%) EpCAM (%) DLL1 (%) 
M1 3.4085 6.9104 10.0106 
M2 1.2495 0.4941 0.8797 
M3 1.7392 0.6350 26.1661 
M4 3.5092 1.0547 23.6094 
Average 2.4766 2.2735 15.1665 
Std Dev 1.1524 3.1004 11.8739 
Table 4.1: Biomarker expression, by sample, 












acquire dose trends for individual biomarkers, however the accuracy of overlapping 
biomarker quantification depends significantly on the precision of the co-registration 
process. For this reason, binning was employed at the threshold step to overcome these 
inaccuracies in the absence of a more direct measure of co-registration fidelity: By 
reducing spatial resolution by a factor of 2, pixel values positive for a given biomarker 
could be matched based on close proximity instead of direct pixel-to-pixel overlay.  
Average results from binned image sets were consistently lower than their non-
binned counterparts and yielded statistically different results for three of the twelve 
groups (controls, LD, MD, and HD groups for ALDH1, EpCAM, and DLL1), with non-
trivial (p < 0.10) differences observed in another two groups. These results are 
inconsistent with our expectations: In theory, the binning should have at the very least 
kept the values equal, if not led to an increase in the number of recorded overlaps. After a 
detailed re-evaluation of the overlap quantification script, it was determined that the code 
may have been incrementally increasing the total tissue volume, which lead to decreased 
overlap values in most cases. The script was subsequently re-worked and the results for 
1x1, 2x2, 3x3, 4x4, 6x6, and 8x8 pixel bins were calculated for a single ALDH1/EpCAM 
example set (Figure 4.2) to demonstrate successful rectification of the problem and the 
B 
Figure 4.1: Visual inspection of DLL1 (A) and EpCAM 
(B) outliers reveals unusually low levels of DLL1 








gradual increase in overlap that one would expect if the co-registration code were not 










 The gradual increase does suggest that co-registration errors exist, however the 
fact that the trend does not plateau for the larger bins suggests that either the error in co-
registration is significantly larger than our image resolution or that the larger bins are 
including a significant number of false-positives.  In either case, further investigation of 
the co-registration process and its associated errors will be warranted in order to provide 
certainty to any statements regarding overlapping pixel regions.  
 
4.2  Dose Response 
Perfusion imaging (Fig 4.3 and 4.4) results demonstrate that 40mg/kg doses, 
corresponding to the MD tumor group, increased oxygen perfusion in the SUM149 
tumors and decreased mean transit time compared to control values. This suggests that 
DC101 doses of around 40mg/kg are having the desired normalization effect on tumor 
Figure 4.2: Binning effects for ALDH1/EpCAM overlap regions for a 





































vasculature, allowing for greater blood flow through the tumor. Additionally, high 
DC101 doses (120mg/kg) are shown to decrease perfusion and increase mean transit time 
when compared to control values, demonstrating previous conclusions that high 
concentrations of angiogenic inhibitor can disrupt tumor vasculature such that hypoxic 
conditions within the tumor volume are worsened. These results will allow the dose 
response of the target biomarkers to be discussed in the context of tissue oxygenation and 
perfusion. 
Our method demonstrates a gradual decrease in ALDH1 expression with increasing 
DC101 dose, which begins to rise again after a certain dose point. The difference was 
strongest for the 40mg/kg dose cohort, which showed a statistically significant 71% 
decrease in expression compared to the control tumor group. ALDH1 expression then 
nearly doubled between the 40mg/kg and 120mg/kg dose cohorts. These results are in 
line with our predictions that a low-dose regimen will increase tumor oxygenation (an 
observation further corroborated by our perfusion imaging data) and decrease processes 
associated with hypoxia-induced CSC proliferation. EpCAM expression exhibited a 
similar dose response pattern to ALDH1, however significant variation within all but the 
120mg/kg dose category precluded any statistically significant patterns from emerging. 
Removal of the aforementioned extraneous data point (control mouse 1) improves the 
variation of the control group and brings the average EpCAM expression of the control 
group below that of the 10mg/kg (LD) dose group (Figure 4.5). These data suggest that 
EpCAM expression occurs independent of DC101 dose for the concentrations under 

















DLL1 expression decreased with both 10mg/kg (LD) and 40mg/kg (MD) doses of 
DC101 by relatively similar amounts, compared to the control group, then increased 
dramatically back to expression levels near that of the control group at 120mg/kg. 
Removal of the aforementioned extraneous data point (control mouse 2) improves the 
deviation in the control group and points to a potentially significant decrease in DLL1 
expression between the control tumor group and the LD/MD tumor groups (Figure 4.6). 
These data suggest that DLL1 activity can be decreased through low-level administration 
of DC101 and the associated improvement of hypoxic conditions within the tumor 
volume. As dose increases and tumor vasculature is cut off, DLL1 expression increases 
significantly compared to the LD/MD tumor groups; increased severity of hypoxic 




Figure 4.3: Changes in tumor perfusion and 







































Figure 4.4: Mean transit time was 
determined as a function of DC101 dose 
based on data in Figure 4.2.1. Data are 
trending towards greater efficiency in the 
























































4.3   Biomarker Overlap 
Regions of overlap between ALDH1 and EpCAM were found to consistently 




























Dose Response of EpCAM to DC101 w/o 
Extraneous Data Point
Figure 4.5: Dose Response of EpCAM to DC101, excluding the mouse 






























Dose Response of DLL1 to DC101 w/o Extraneous 
Data Point
Figure 4.6: Dose Response of DLL1 to DC101, excluding the mouse 1 







positive (~2-7%) populations, in both binned and non-binned cases, for all dose 
concentrations. Though we previously demonstrated a lack of dose response by EpCAM 
to DC101, the relative lack of change to overlapping regions with dose suggests that 
those regions positive for both biomarkers are being affected in equal quantity. As we 
have previously demonstrated that ALDH1 expression does decrease with DC101 dose, 
EpCAM expression would have to also decrease in order for the amount of overlap to 
remain as constant as it is. This suggests that with a larger sample size, it may be possible 
to reduce the variations observed in Figure 3.2.2 and show that the observed expression 
trend does in fact mirror that of ALDH1. However, these inconsistencies may also be 
indicative of errors in the co-registration process. 
ALDH1 was found to overlap much more significantly with DLL1-positive 
populations in the control group; nearly 20% of all ALDH1-positive pixels also tested 
positive for DLL1 expression, in both non-binned and binned cases. These regions of 
overlap decreased dramatically with the addition of DC101, down to between 4-5% (2-3% 
in binned image sets) however large variations in expression values preclude any 
statistical significance (p < 0.05) between these groups. This suggests the possibility that 
if ALDH1 expression is being scaled back due to increased perfusion, then it is 
happening in regions that are also positive for DLL1 expression. At high doses, overlap 
was found to increase significantly (p < 0.05) from both LD and MD tumor group levels. 
These results agree with our previous assessment that high DC101 doses caused 
increased ALDH1 activity and that increases in ALDH1 are occurring in regions that are 







DLL1, conversely, exhibited a constant decrease in overlap with increasing dose, 
ranging from ~5% (4% in binned image sets) in the control tumors down to ~ 2% (1% in 
binned images) in the high-dose tumors. However, our previously-stated results 
demonstrate that both DLL1 and ALDH1 expression significantly increases in the HD 
tumor group with respect to the MD tumor groups. These findings suggest that while both 
ALDH1 and DLL1 expression vary with DC101 dose, variations in DLL1 expression are 
occurring independently of ALDH1. 
The relationship between EpCAM and DLL1 with respect to overlap is similar to 
that observed between DLL1 and ALDH1: Overlap between EpCAM-positive and 
DLL1-positive regions account for nearly 20% of EpCAM-positive populations, however 
these same regions only account for ~5% of DLL1-positive populations; LD and MD 
groups see a decrease in overlap down to 4-5% of total EpCAM expression, which is 
statistically indistinguishable from the observed 2-3% of total DLL1 expression due to 
deviations in the average; in the HD group, overlap again increases to account for nearly 
30% of overall EpCAM expression, while only accounting for a paltry 4% of overall 
DLL1 expression. Again, as we have established that DLL1 dramatically increases in the 
HD tumor group with respect to the MD group (Figure 3.2.3), this suggests that DLL1 
expression is varying independently of EpCAM expression. 
4.4 Conclusions and Future Direction 
Using an in-house imaging threshold technique, we were able to demonstrate a 
dose response relationship between ALDH1 and the VEGFR inhibitor, DC101. 
Additionally we were able to show that DLL1 expression may also share a dose response 







demonstrate a dose response to DC101. Overlapping studies, though complicated by 
binning issues, showed that a potential relationship may exist between EpCAM and 
ALDH1 expression, and that ALDH1 and EpCAM expression may be closely correlated 
with DLL1 expression. ALDH1 quantification was used to partially validate our 
technique, though future studies should include more robust validation measures. 
Through a combination of biomarker expression and perfusion imaging data, we 
were able to show that normalization of tumor vasculature is possible and likely occurs 
around DC101 dose concentrations of 40mg/kg, alleviating hypoxic conditions within the 
tumors and decreasing the hallmarks of CSC populations. Accurately defining this “dose 
window” will be the key to the clinical applicability of this research; the data and 
methods covered herein represent the foundation of studies intended to identify and 
control CSC populations through AAT, thereby improving clinical outcomes for cancer 
patients. 
In addition to further validation of this technique, future aims will attempt to 
incorporate Principle Component Analysis into the imaging procedure. Unlike the 
thresholds used in this experiment, which separate positive and negative expression 
values based on a single color channel, PCA techniques use a color deconvolution 
algorithm to decouple the contribution of each channel to a given stain20. Finally, 
attempts will be made to co-register IHC slides with DCE-CT and PCT-S images in order 
to identify an imaging parameter that varies with changes in CSC biomarker expression. 
If successful, future cancer therapy treatments will be able to use existing imaging 
modalities to monitor proliferation and migration of CSC populations from and within the 
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